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Complementary and alternative medicine
and consumer law
Professor Michael Weir,' Dr Jon Wardle,f Associate
Professor Brenda Marshall* and Eloise Archer§
The application of consumer Law has become significant in the health sector
including the provision of complementary and alternative medicine. Many
legal authorities in this area deal with extreme examples of breaches of
consumer law which provides a problematic image for the evidence base for
this form of health care especially when high quality scientific is sought in
regard to representations made. The article discusses the fact that in some
contexts traditional use evidence is applied in regard to the determination of
appropriate indications of use for the registration and listing of
complementary and alternative medicine but this does not appear to be
applied in consumer law decisions. The capacity to provide high quality
scientific evidence is limited for many form of complementary and alternative
medicine based upon their historical background and approach to healing.
Based upon an analysis of the value obtained from scientific evidence for
complementary and alternative medicine this article argues for a broader
use of traditional evidence and other forms of evidence to support
compliance with consumer legislation in a context of where public safety is
preserved.
Introduction
There have been a number of examples in recent years of worrying breaches
of consumer legislation in relation to misleading or deceptive conduct by
CAM practitioners.1 The regulation of CAM is important owing to its
significant but underrated role in the Australian health sector. In 2007, a study
found that national expenditure for CAM medicines was $4.1 billion, and that
the estimated number of visits to CAM practitioners by adult Australians in a
12-month period (69.2 million) was almost identical to the estimated number
of visits to medical practitioners (69.3 million).2 In some areas of Australia,
CAM practitioners providing primary care services outnumber conventional
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1	ACCC v Allergy Pathway Fry Lid [2009] FCA 960: BC200907920; ACCC y NuHra Health
Ply Lid (in liq) (2007) ATPR (Digest) 46-273; (2007) ASAL 55-172; [2007] FCA 695;
BC200703471: Commissioner of Fair Trading. Department of Commerce v Hunter [2008]
NSWSC 277; BC200802120; 1 Freckelton, 'Death by Homeopathy: Issues for Civil,
Criminal and Coronial Law and for Health Service Policy' (2012) 19 Jnl of Law and
Medicine 454 at 464.
2	C C Xuc el al, 'Complementary and Alternative Medicine Use in Australia: A National
Population-Based Survey' [2007] (July-August) 13 (6) Jnl of Alternative and
Complementary Medicine 643 at 643.
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primary carc physicians.3 As only chiropractors, osteopaths and traditional
Chinese medicine practitioners in Australia are subject to specific statutory
regulation and disciplinary enforcement processes, the ability to apply
disciplinary procedures to suspend or exclude other CAM practitioners from
practice is generally not available.4 In New South Wales under the NSW
Public Health Act 2010, the Code of Conduct for Unregistered Health
Practitioners5 and provisions of the Health Care Complaints Act,6 it is
possible to grant prohibition orders or place conditions on the practice of
unregistered health practitioners who are found to be in breach of the
provisions of the Code of Conduct or consumer legislation. Similar provisions
now apply in South Australia under the Unregistered Health Practitioners:
Code of Conduct — Health and Community Services Complaints Regulations
2005.7 In practice, these provisions have been used for the removal of grossly
unethical practitioners and do not offer public protection for 'minor' breaches
such as financial exploitation and misleading claims by practitioners.8
Other unregistered CAM practitioners not subject to the above regime such
as homoeopaths, herbalists, naturopaths and massage therapists are
self-regulated by voluntary membership of professional associations with
possible disciplinary actions involving fines, reprimands, suspension or
exclusion from membership.9 Even if the most substantial penalties of
suspension or exclusion are applied by these bodies, they do not require a
practitioner to cease practice, though it may result in the practitioner losing
access to private insurance rebates or GST exemption for their services.10
These arrangements have sometimes been inadequate, with some professional
associations refusing to deregister practitioners known to be practising
unethically due to concerns that a practitioner might respond by conunencing
legal action in response."
One means of regulating the practices of unregistered health practitioners is
through consumer legislation and, in particular, through the provisions of the
3	i Wardle ct al, 'Dislribillion of Complementary and Alternative Medicine (CAM) Providers
in Rural New South Wales, Australia: A Step towards Explaining High CAM Use in Rural
Health?' (2011) 19(4) A us I Jnl of Rural Health 197 at 199.
4	Available for registered practitioners under s 196 of the Health Practiuoner Regulation
National Law Act 2009 (Qld) (National Law). Some restricted acts under s 123 of the
National Law prohibit a person from certain acts, such as manipulation of the cervical spine,
unless specified as an appropriate practitioner. This regulation would apply lo unregistered
heal l h practitioners.
5	Public Health Regulations 2012 (NSW) Sch 3.
6	Health Care Complaints Act 1993 (NSW) ss 41 A, 41 A A.
7	Health and Community Services Complaints Regulations 2005 (SA) Sch 2.
8	Australian Health Ministers Advisory Council, Consul ration Paper: Options for Regulation
of Unregistered Health Practitioners. February 2011. p 31.
9	M Weir, Law and Ethics in Complementary Medicine: A Handbook for Practitioners in
Australia and New Zealand, 4th ed. Allen and Unwin, Crow's Nest, NSW, 2011, pp 6-7.
10	ibid, p 251.
11	For example, the NSW Code of Conduct for Unregistered Practitioners was developed
largely in order to remove from practice a Newcastle naturopath (Paul Perret), who had
faked his qualifications and had previously been convicted of fraud and armed robbery, after
his association refused to deregister him for fear he may sue. This is discussed in
Parliamentary Hansard. New South Wales, Parliamentary Debates, Legislative Assembly,
30 November 2005, p 161; 20388, Mr Matthew Norris, New South Wales Legislative
Assembly, 2005; New South Wales Parliamentary Debates, Hansard, p 161: 20388.
Complementary and alternative medicine and consumer law 87
Australian Consumer Law (ACL) under the Competition and Consumer Act,12
which deals with misleading and unfair practices. This article focuses on the
standard of evidence required in recent consumer protection decisions in
regard to CAM cases. This analysis will reveal that judicial decisions in CAM
cases usually reflect the scientific evidence based perspective of orthodox
medicine (OM). This article will also consider whether, taking into account
the healing philosophy of CAM, the need for scientific evidence to justify
representations is appropriate when this perspective does not fit easily with the
traditions and clinical approach of many CAM modalities.
What is CAM?
CAM has been defined as therapies not taught in US medical schools.13 The
British Medical Association defined non-conventional therapies as 'those
forms of treatment which are not widely used by orthodox health-care
professions, and the skills of which are not taught as part of the undergraduate
curriculum of orthodox and paramedical health-care courses'.14 Some types of
CAM are called 'alternative medicine'. This may aptly describe the clinical
approach of some practitioners of modalities such as traditional Chinese
medicine or homoeopathy. These modalities seek to provide an alternative to
orthodox medicine as complete systems of healing not limited to a part of the
body or a limited set of treatment options.15 Complementary medicine is
intended to complement orthodox medicine and is particularly applicable to a
therapy like therapeutic massage. In this article the term 'complementary and
alternative medicine' (CAM) will be used in an attempt to incorporate the
widest possible scope for the various modalities although it is acknowledged
it perpetuates the tendency to define these therapies or models of healing from
the perspective of orthodox medicine.16 Complementary and alternative
medicine is applied by practitioners who specialise in one or a number of
modalities as exampled by chiropractors, osteopaths, naturopaths, western
herbalists, traditional Chinese medicine practitioners, homoeopaths and
massage therapists.
AppHcation of the Australian Consumer Law to CAWl
Freckelton has commented that:
Actions brought under Australian States' fair trading legislation or by the Australian
and Competition and Consumer Commission (ACCC) under the Trade Practices Act
12	Competition and Consumer Act 2010 (Clh).
13	M S Micozzi, 'CharactcrisUcs of Complementary and Alternative Medicine' in M S Micozzi
(Ed), Fundamentals of Complementary and Alternative Medicine, Churchill Livingstone,
London, 1996, p 5; I) M Eisenherg, 'Advising Patients Who Seek Alternative Medical
Therapies" (1997) 127 Annals of Internal Medicine 61 at 61.
14	British Medical Association, above n 9, pp 7-8; W B Jonas. 'Alternative Medicine-Learning
from the Fast, Examining the Present, Advancing to the Future' (1998) 280 Jnl of the
American Medical Association 1616 at 1616.
15	British Medical Association, above n 9, p 7.
16	N Gevitz. 'Three Perspectives on Unorthodox Medicine' in N Gevitz (Ed), Other Healers:
Unorthodox Medicine in America, John Hopkins University Press, Baltimore MD, 1988, p 2;
M H Cohen, Complementary and Alternative Medicine: Legal Boundaries and Regulatory
Perspectives, John Hopkins University Press, Baltimore Ml), 1998. p viii.
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1974 (Cth) and now under Ch 2 of Sch 2 to the Compeliiion and Consumer Act 2010
(Clh) have emerged as an increasingly important tool in the regulation of both
registered and unregistered health practitioners.17
This reflects a strategy of the ACCC to focus on health praclilioners and
representations about health products and services in applying its regulatory
function, which is expressed in the authorities discussed in this article.18 The
case law provides examples of serious misconduct by CAM practitioners
characterised by very expensive treatments for serious and potentially life
threatening illnesses for vulnerable patients, often involving a practitioner
with doubtful or non-existent training and qualifications. These cases
normally entail the application of therapies that lack any supporting evidence
of efficacy or safety, often with a lack of information provided to the patient
about the nature of the treatment offered and the state of scientific evidence to
support the application of the therapy.19 These circumstances typically result
in breaches of consumer legislation.
Relevant sections of the ACL that arise in relation to these matters include:
Section 18 Misleading or deceptive conduct
A person must not, in trade or commerce, engage in conduct that is misleading or
deceptive or is likely to mislead or deceive.
Section 29 False or misleading representations about goods or services
A person must not, in trade or commerce, in connection with the supply or
possible supply of goods or services or in connection with the promotion by any
means of the supply or use of goods or services:
(a)	make a false or misleading representation that goods are of a particular
standard, quality, value, grade, composition, style or model or have had a
particular history or particular previous use;
(b)	make a false or misleading representation that services are of a pardcular
standard, quality, value, or grade;
(g) make a false or misleading representation that goods or services have
sponsorship, approval, performance characteristics, accessories, uses or
benefits;
Section 33 Misleading conduct as to the nature etc of goods
A person must not, in trade or commerce, engage in conduct thai is liable to
mislead the public as to the nature, the manufacturing process, the characteristics,
the suitability for their purpose or the quantity of any goods.
Section 34 Misleading conduct as to the nature etc of services
A person must not, in trade or commerce, engage in conduct that is liable to
mislead the public as to the nature, the characteristics, the suitability for their
purpose or the quantity of any services.
17	I Freckclton, 'Unscientific Health Practicc and Disciplinary and Consumer Protection
Litigation' (2011) 18(4) Jul of Law and Medicine 645 at 654.
18	ACCC, Medical, Health Service Providers Warned on Advertising, 20 July 2000, at
<hltp://www.accc.gov.au/contcnt/ index.phtml/ilemId/87430/l'romItemld/622975> (accessed
17 June 2013). Note ihe recent commencement of action by the ACCC in regard to
representations by a homoeopath in regard to a homoeopathic vaccine for whooping cough.
See ACCC, ACCC Takes Action over Potentially Misleading Vaccine Claims. 21 February
2013, at <http://vvww.accc.gov.au/media-rclcase/accc-takes-action-over-potentially-
misleading-vaccine-claims> (accesscd 17 June 2013).
19	Freckelton, above n 17, at 665.
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A number of 'well-established propositions' underpin the application of the
above provisions:20
•	in considering the effect of allegedly misleading conduct on a class
of persons such as consumers who may range from the gullible to the
astute, the court must consider whether the 'ordinary' or 'reasonable'
members of that class would be misled;
•	conduct causing confusion and wonderment is not necessarily
co-extensive with misleading conduct;
•	there is no requirement that the impugned conduct must be intended
to mislead — a contravention of the ACL's misleading conduct
provisions can be established even though a party acted reasonably
and honestly; and
•	the words 'likely to mislead or deceive' in s 18 make it clear that it
is not necessary to demonstrate actual deception to establish a
contravention of that provision.
Consumer case law and complementary medicine
One significant aspect of most of the cases discussed below is that there was
little, if any, evidence provided by the defendant to support the representations
made. This limits the level of guidance provided by those cases as against
making representations based upon a supportable evidence base. In regard to
the level of evidence made available by the defendant in this manner, the case
law can be categorised as follows:
1.	No evidence provided by the defendant against the plaintiff scientific
evidence {Purple Harmony,2i Commissioner of Fair Trading,
Department of Commerce v Perrett;21 ACCC v NuEra Health Ply Ltd
(in liq)',22 ACCC v Jones'24 Willesee Healthcare) 25
2.	Limited evidence provided by the defendant against plaintiff
scientific or professional evidence {Advanced Allergy Elimination
Pty Ltd'26 Commissioner of Fair Trading, Department of Commerce
v Hunter).21
3.	Some general scientific evidence provided by the defendant against
plaintiff scientific and professional evidence {Giraffe World).2*
20	Google Inc. v ACCC (2013) 294 ALR 404; 87 AUR 235; [2013] HCA 1; BC201300295
al r61-[9]. Although the High Court's primary locus in this case was on s 52 of the TPA (now
s 18 of the ACL), these propositions can be extrapolated to the other misleading
conduct/representation provisions in that legislation.
21	ACCC v Purple Harmony Plates Pty Ltd [2001J FCA 1062; BC200104454.
22	Commissioner of Pair Trading, Department of Commerce v Perrett [2007] NSWSC 1130;
BC200708733. '
23	ACCC v NuEra Health Pty Ltd (in liq) (2007) ATPR (Digest) 46-273; (2007) ASAL 55-172;
[2007] FCA 695; BC200703471.
24	ACCC v Jones (No 5) [2011] FCA 49; BC201100263.
25	ACCC v Willesee Healthcare Ply Ltd [2011] FCA 301; BC201102045.
26	ACCC v Allergy Pathway Pty Lid [2009] FCA 960; BC200907920.
27	Commissioner of Fair Trading. Department of Commerce i' Hunter [2008] NSWSC 277;
BC200802120.
28	ACCC \> Giraffe World Australia Ply Lid (1999) 95 FCR 302; 166 ALR 74; [19991 FCA
1161; BC9905234.
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4.	Scientific evidence provided by the defendant against plaintiff
scientific and professional evidence {Operation Smile (Australia)
Inc).29
5.	Traditional evidence against plaintiff scientific and professional
evidence — this has not arisen in the case law.
A significant authority dealing with misleading or deceptive behaviour
relevant to complementary medicine is ACCC v Purple Harmony Plates Pty
Ltd.7,0 This matter related to the representations made in relation to a product
called 'Purple Harmony plates', which came in different forms including
disks, angels, phone disks and fridge fresheners. These products were said to
have many and varied therapeutic benefits, including; negating the effects of
electromagnetic radiation; accelerating healing; calming people; increasing
health; decreasing stress levels; strengthening the immune system; treating
cuts, bums, aches and pains; green thumbs to treat water and a fuel ionizer
system to treat fuel and improve its efficiency.31
The ACCC argued that these representations made on a website and in
certain publications suggested these products had performance characteristics
they did not possess and were misleading or deceptive or likely to mislead or
deceive,32 contrary to ss 52 and 53(c) of the Trade Practices Act 1974 (Cth).33
The ACCC relied upon s 51A of the Trade Practices Act34 and argued that the
representations were as to future matters that could not be substantiated.35
This provision placed the burden of proof upon a party who had made a
representation about a future matter to demonstrate that it had reasonable
grounds for making (he representation, otherwise the representations would be
deemed to be misleading.
The court held that the defendant had represented the products possessed
(he performance characteristics claimed and that these representations made
claims as to future matters and suggested that a person who purchased the
product would derive the stated benefits from the product.36 The defendant did
not provide any substantial evidence to support the assertions made that would
address the question of whether the company had any reasonable grounds for
making the representations.37 Accordingly, the representations were deemed
to be misleading.38 The court ordered injunctive relief against the respondents
making these representations and required refunds to customers and corrective
advertisement.39
Similar issues arose in Commissioner of Fair Trading, Department of
29	Noone, Director of Consumer Affairs (Vic) v Operation Smile (Australia) Inc [2012] VSCA
91; BC201202920.
30	ACCC v Purple Harmony Plates Pty Ltd [2001] FCA 1062; BC200104454.
31	Ibid, at [17],
32	Ibid, at [10].
33	Now s 18 and 29(G) of the ACL.
34	Now s 4(1) of the ACL.
35	ACCC v Purple Harmony Plates Ptv Ltd [2001] FCA 1062; BC200I04454 at [11].
36	Ibid, ai [2l]-[22].
37	Ibid, at [20].
38	Ibid, at [22].
39	Ibid, at [31].
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Commerce v Perrett,40 where the Commissioner sought a declaration that the
defendant Perrett had engaged in misleading or deceptive conduct and conduct
likely to mislead or deceive in contravention of the Fair Trading Act 1987
(NSW).41 It was also suggested he had engaged in conduct that was liable to
mislead the public as to the nature, characteristics and suitability for their
purpose of certain goods in contravention of s 49 of the same legislation.42
The Commissioner sought a restraining order in relation to these types of
activities.43
The court dealt with the defendant's actions in relation to a number of
clients, involving the use of unorthodox substances of uncertain or unknown
composition, the diagnosis and treatment of acute and chronic medical
conditions and (he application of ointments and intravenous injections.44 The
Commissioner suggested that the defendant had represented he had an ability
to treat multiple sclerosis,45 breast cancer,46 a thyroid condition,47 terminal
cancer, Huntington's Disease48 and sympathetic nerve dystrophy.49 The
Commissioner also suggested the defendant made statements suggesting
clients should not rely upon medical treatment and indicating he had access to
knowledge and substances not normally available.50 The defendant was not
able to present evidence to support the representations he made about his
ability to treat those ailments. The plaintiff relied upon s 41(2)51 that placed
the burden of proof upon a person who has made a representation about a
future matter to demonstrate that he or she had reasonable grounds for making
the representation, otherwise the representations would be deemed to be
misleading. The court relied upon statements of clients, and on that basis
Perrett was held to have made representations that were misleading or
deceptive or likely lo mislead or deceive; restraining orders were granted to
stop that behaviour.52
In the same year as the Perrett decision, misleading representations in
breach of the Trade Practices Act were held to have been made by the
respondent company in ACCC v NuEra Health Pty Ltd (in liq).5* The
40	Commissioner of Fair Trading, Department of Commerce v Perrett [2007] NSWSC 1130;
BC200708733.
41	Fair Trading Act 1987 (NSW).
42	Now s 33 of the Competition and Consumer Act 2010 (Cth),
43	Commissioner oj Fair Trading, Department of Commerce v Perrett [2007] NSWSC 1130;
BC200708733 at [2].
44	Ibid, at |6].
45	Ibid, at [9],
46	Ibid, at [25].
47	Ibid, at [56].
48	ibid, at [79 j.
49	Ibid, at [97].
50	Ibid, at [9], [25], [56], [79]. [97].
51	Now s 4(1) of the ACL which provides: 'If: (a) a person makes a representation with respcct
to any future mailer (including the doing of, or the refusing to do, any act); and (b) the
person does not have reasonable grounds for making the representation; the representation
is taken ... to be misleading.'
52	Commissioner of Fair Trading, Department of Commerce v Perrett [2007] NSWSC 1130;
BC200708733 at [134].
53	ACCC v NuEra Health Pty Ltd (in liq) (2007) ATPR (Digest) 46-273; (2007) ASAL 55-172:
[2007] FCA 695; BC20070347I.
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statements in question, which promoted NuEra's products and 'treatments' to
cancer victims via the company's website, were categorised by the ACCC as
the 'cure cancer representations', the 'prolong life representations' and the
'scientific support representations', and condemned by Ryan J as
exemplifying 'conduct of the most reprehensible kind'.34 Tn coming to this
decision, his Honour was scathing of the fact that the respondent had not
adduced any evidence to contradict or 'palliate' the case presented by the
ACCC.55
In ACCC v Jones,56 the ACCC instituted proceedings against Danyl Peter
Jones in respect of alleged contraventions of the Trade Practices Act.57 The
ACCC claimed that a website Mr Jones maintained and a publication authored
by him, entitled 'The Truth about Overcoming Cancer', contained
representations that were misleading or deceptive:
The Darryl Jones Health Resolution Centre methodology is based on the
resolution of life-threatening diseases without dispensing pharmaceutical drugs,
advocating radium therapy, surgery, or harmful ehemothcrapy — focusing instead
on a three-step Triune Wellness Offensive — utilizing nutrition, exercise, and
vitamins, along with close, professional, personal accountability.
The Darryl Jones Health Resolution Centre — committed to your total victory
over modern day life-threatening diseases — with time-proven personal strategies
empowering you with the tools you need for a prolonged life, greater health, and real
hope for the future.58
The crux of the matter is that Cancer Loves Glucose and glucose is easily
obtainable from many of the vast majority of foods that we ingest daily. So to take
away its major source of nutrition will deprive it of 'its life source' and therefore
compromise its ability to persist and grow. This access to Glucose helps to explain
the awesome rise in new cases of cancer, at a rale which is unprecedented at any time
in our history. It is a modern day epidemic!59
On behalf of the ACCC, physician Dr Snyder FRACP indicated that there was
cither limited or no scientific evidence for these types of representations.60 On
the balance of this evidence, there was a finding by the court that the
statements were misleading or deceptive.61 Although this matter was an
interlocutory injunction that did not involve a full statement of claim, there
was little discussion of the connection between the evidence adduced by the
ACCC and the statements that were impugned with the ACCC's request to
grant an injunction seemingly readily accepted once the report of Dr Snyder
was provided. This would indicate that the scientific report was accepted as
the basis of the finding of misleading or deceptive conduct apparently in the
absence of any substantive evidence from the defendant.
54	Ibid, at [8], [6J.
55	Ibid, at [6].
56	ACCC v Jones (No 5) 12011] FCA 49; BC201100263.
57	Ibid, al []J.
58	Ibid, at [2].
59	Ibid, al [5|. The issue here most likely was the absolutist language used. This suggests the
need to not represent beyond the data or be moderate in your conclusions etc and 'refcrcnee
to Emerging' evidence etc.
60	Ibid, at L8].
61	Ibid, at [10],
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Tn ACCC v Advanced Allergy Elimination Ply Ltd,62 an action was
commenced by the ACCC against the respondent Advanced Allergy
Elimination (AAE), which operated clinics for the diagnosis and treatment of
allergies. The methods by which AAEi diagnosed and treated allergies
included testing for and identifying a person's specific allergies using a muscle
strength indicator technique and treating allergies by using a technique based
on positive and negative conditioning.63 AAE advertised on an interact
website, on radio, in newspapers and in brochures given to clients, prospective
clients and other interested persons.64
The ACCC alleged that certain statements published on the website and
contained in the advertisements were in breach of the Trade Practices Act.65
The impugned statements related to the ability of AAE to test for and identify
a substance to which a person was allergic, that it could cure or eliminate
virtually all allergies or allergic reactions, that it could successfully treat a
person's allergies or allergic reactions and that its treatment was safe or
involved low risk.66 These allegations were upheld based upon evidence
provided by a Professor Douglass, the Head of the Allergy, Asthma and
Clinical Immunology Service at the Alfred Hospital, who suggested there was
little or no scientific evidence for the statements impugned in the action.67 The
assumption appeared to be that, as there was limited scientific evidence for the
statements, accordingly they were misleading or deceptive.
In a similar factual circumstance in ACCC v Willesee Healthcare Pty Ltd,68
the court determined that representations by the respondent about treating
allergies through kinesiology and acupressure and thereby being able to cure
or eliminate all, or virtually all, allergies or allergic reactions were misleading
and deceptive representations, also based upon the expert evidence of
Professor Douglass.69 This conclusion was reached in the absence of other
evidence to the contrary.
Tn Commissioner of Fair Trading. Department of Commerce v Hunter,70 an
injunction was sought against Hunter, who practiced as a naturopath and
medical herbalist. The primary focus of the case was in relation to his
advertising of 'live blood analysis', which was said to allow diagnosis of
ailments instantly and to assist in the treatment of such illnesses that the
Commissioner suggested was a misleading representation under the tenns of
the Fair Trading Act.71 Also of concern in this matter were the representations
made about the qualifications of Mr Hunter and his ability to diagnose and
treat serious health conditions.72
Mr Hunter used the titles 'Dr', 'Doctor of Natural Medicine' and PhD in
62	ACCC v Allergy Pathway Pry Lid [20091 FCA 960; BC200907920.
63	Ibid, at [I j.
64	Ibid.
65	Ibid.
66	Ibid, at [2].
67	Ibid, at [4J.
68	12011] FCA 301; BC201102045.
69	Ibid, at [33J.
70	|2008] NSW.SC 277; BC200802120.
71	Fair Trading Act 1987 (NSW) ss 42,44 (e) and (0 and 50 ...
72	Commissioner of Fair Trading, Deparlmenl of Commerce v Hunter [2008] NSWSC 277;
BC200802I20 at [2],
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advertisements as well as words that eould suggest he was a medical doctor.73
As Mr Hunter was not a medieal doctor, these representations were considered
to be misleading or deceptive representations.74 Also deemed to be misleading
or deceptive was the representation that he was competent to treat serious
illnesses such as high blood pressure and a list of other conditions.75 Evidence
was adduced from Professor Eva Raik, a hacmatologist with extensive
qualifications and experience about the efficacy of live blood analysis and the
difficulty in ascertaining medical conditions or making therapeutic decisions
or diagnosis from that type of study.76 There was limited evidence produced
by Hunter in relation to the evidence basis for this therapy. The court found,
on the basis of the expert evidence, that the representations in regard to the
value of live blood analysis were misleading or deceptive or likely to mislead
or deccive.77 The court ordered that Mr Hunter be permanently restrained
from carrying on a business or in any way providing in trade and commerce
naturopathy, medical herbalism, herbalism, iridology. hydrotherapy, sports
medicine, osteopathy and blood analysis.78
The case ACCC v Giraffe World7'* involved the marketing of an 'ion mat'
(the mat) by the first respondent Giraffe World. The mat or mattress was
connected to a source of electricity. There is nothing in the Judgment to
suggest this item had been listed as a therapeutic device under the Therapeutic
Goods Act.80 The ACCC alleged that Giraffe World made misrepresentations
in contravention of ss 52 and 53(c) of the Trade Practices Act,81 in suggesting
that as a result of its emission of negative ions the mat benefited the health of
persons who slept on it.82 Giraffe World provided some expert testimony to
support these assertions, including evidence from an experienced
naturopath,83 a chiropractor84 and an academic engineer.85 There was also
reference to a published article by a Japanese professor about the impact of
these types of equipment on the human body, though without suggesting any
particular health benefits.86
The ACCC adduced evidence from an array of medical doctors and
university experts in physics about the performance and impact of the mat.
The judge concluded that the weight of the evidence provided by the ACCC
suggested he should prefer the view of the ACCC, and this resulted in the
73	He also misrepresented his alma mater (Medicina Alternativa — an unaccredited diploma
mill) as MA, which was suggested could have reasonably been interpreted as meaning a
Master of Arts. Even the Phi) was deemed as misleading, as it was not a recognised
qualiiication.
74	Ibid, at [351.
75	Ibid, at [71.
76	Ibid, at [511.
77	Ibid, at [541.
78	Ibid, at [1311.
79	(1999) 95 FCR 302; 166 ALR 74; [19991 FCA 1161; BC9905234.
80	Section 4IBD (describe what legislation stipulates).
81	Now s 18 and s 29(g) of the ACL,
82	ACCC v Giraffe World Australia Pty Lid (1999) 95 HCR 302; 166 ALR 74, 77: [1999] FCA
1161; BC9905234 at [21.
83	Ibid, at [127].
84	Ibid, at [129].
85	Ibid, at [130].
86	Ibid.
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court delcrmining (he represenlalions were misleading or deceptive.87 This
case process further entrenches the view that statements made about a piece
of equipment should be supported by scientific evidence, otherwise there is a
possibility of a finding of a breach of consumer legislation.
A significant authority that deals directly with the issue of what type of
evidence is required to avoid a finding that an activity is deemed misleading
or deceptive is Noone, Director of Consumer Affairs Victoria v Operation
Smile.** Four respondents (collectively. Operation Smile) operated the 'Hope
Clinic', described as a complementary medicine centre specialising in the
treatment of cancer. Operation Smile's website described the treatments
offered at the Hope Clinic for a long list of serious medical conditions such as
cancer and HTV and contained statements relating to the efficacy of these
treatments based upon peer reviewed and published methods of cancer
treatment;89 it claimed that the techniques used at the clinic included
state-of-the-art medical technology and subtle energy therapies such as
homoeopathy and acupuncture.9" The Director of Consumer Affairs alleged
that Operation Smile engaged in misleading or deceptive conduct in trade or
commerce contrary to s 9( I) of the Fair Trading Act 1999 (Vic)91 on the basis
that the statements falsely represented that the treatments offered by Operation
Smile treated cancer effectively based upon scientific evidence.92 Operation
Smile admitted these statements were made but denied that they were
misleading or deceptive 93
Interestingly, at first instance Pagone J held that the Operation Smile
treatments did not have the support of conventional sciencc and, according to
conventional science, were of no benefit to cancer sufferers.94 Nevertheless,
his Honour determined that readers of the statements would understand them,
in their context, as mere expressions of opinion and as claiming no support
from conventional medicine or science leading to a finding that the activity
considered was not misleading or deceptive.95 On appeal, the Court of Appeal
did not endorse this view and the other views expressed by the trial judge in
relation to the statements made by the Hope Clinic.
The Court of Appeal held the net effect of the statements was that the
treatments offered were as scientifically based and rigorously tested as those
of conventional medicine based upon an assessment of the whole of the
context within which the statements were made.96
87	Ibid, at [114].
88	[2012] VSCA 91; BC201202920.
89	Ibid, at [56].
90	Ibid, at [67].
91	Now s 18 of l he ACL.
92	Noone. Director of Consumer Affairs Vicioria v Operation Smile (Australia) Inc [2012]
VSCA 91; BC201202920 at [52].
93	Ibid, at [61], [113].
94	Noone. Director of Consumer A ffairs Victoria v Operation Smile (Australia) (No 2) [2011]
VSC 153; BC201102208 at [16J.
95	Ibid, at [52], [65], [77], [81].
96	Noone, Director of Consumer Affairs Vicioria v Operation Smile (Australia) Inc. [2012]
VSCA 91; BC201202920 at [59].
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As appears from what is set out above, the contexi included the claim that the Hope
Clinic adopted an integrated approach to the treatment of chronic illness combining
state-of-the-art medical technology with alternative therapies; the explicit
description of Hope Clinic therapies as the best scientific complementary medicinc;
the ostensibly scientific names ascribed to the therapies offered by the Hope Clinic,
such as 'photo dynamic therapy', 'Holt Microwave therapy' 'Oxygen therapy' and
'Biolife electrotherapy'; the assertion as to practitioners of complementary medicine
not hesitating 'to employ conventional medical practices'; the explicit assertion that
the Hope Clinic's combination of alternative treatments with conventional medicine
would optimize a patient's treatment plan; and the surely very remarkable claim that:
The network of colleagues who make up this institute are committed to reading and
researching all published information. We contact scientists and physicians all over
the world to learn at first hand from these eminent colleagues in hospitals,
universities and laboratories.97
Although the Court of Appeal allowed the appeal and held that the statements
discussed in the case were misleading or deceptive, this decision is significant
in that it indicated that, if precision is applied to statements made which
provide clarity for the reader about the basis of the evidence to support the
statements made that a breach of the misleading or deceptive conduct
prohibition might be avoided.
How have courts dealt with the provision of scientific
evidence?
Although in most of the above cases there was limited, if any, substantive
evidence to justify the representations made, the unexpressed assumption
from these cases is that it is incumbent to provide high quality scientific
evidence for the representations, otherwise a finding of misleading or
deceptive conduct is easily made. This assumption is not applied in non-health
related matters involving misleading or deceptive conduct.98 It seems in all
cases involving health practices that this form of evidence is required.
Freckelton acknowledges that members of the general public are entitled to
hold views that do not accord with scientific orthodoxy as long as they do not
cause harm to others. Freckclton suggests:
there is a constructive role for the law in preventing unscientific health practices so
that vulnerable patients are not harmed or at least in regulating how such practices
are advertised so that iheir lack of scientific legitimacy, assessed by the reference
point of evideneed-based practice, is made unequivocally apparent to prospective
patients so that representations based upon them will not be false, misleading or
deceptive. If an accurate, evidence-based picture is given of the unlikelihood of
practices or treatments having a beneficial effect, or the likelihood of their having a
counter-therapeutic outcome, from the perspective of conventional science, then
patients can make their own informed decisions as to whether to submit to such
practices and treatments. However, the power imbalance in the practitioner-patient
97	Ibid.
98	Refer to case law below.
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relationship always has the potential to militate against the real exercise of
autonomy in such circumstances and can lead to dangerous reliance upon spurious
and exploitative health practice."
There is not a lot to disagree with in this approach. However, as discussed
below there is a case for a greater acknowledgement in this context of
traditional evidence and other forms of scientific evidence to determine
whether a CAM practitioner is being misleading or deceptive in his or her
representations.
Is there an arguable basis to require scientific evidence in relation to serious
illnesses where the practitioner is undertaking the role of primary health
practitioner?100 Does the strict test apply to every statement, representation
word or gesture by all practitioners to every client?
Under current circumstances it is not practical to require scientific evidence
for every statement by a CAM practitioner, and the law generally does not
require this in other contexts.101 When determining whether a practitioner was
negligent in statements made, it is relevant to consider the tort of negligent
misstatement which aims to redress any economic loss from that statement.102
Negligent misstatement, is a species of the tort of negligence, is arguable
when a party who has a special skill or competence or in the course of
business assumes responsibility for the accuracy of a statement, advice,
information or an opinion to another party in circumstances where the other
person reasonably relied upon the advice, information or opinion and as a
result a duty of care arises in regard to that advice.103 The first person may be
liable for economic loss or damage caused if the advice, information or
opinion was given negligently. Reference is necessarily made to peer opinion
based upon the terms of the civil liability legislation in the case of a person
deemed a 'professional'104 or, if not applicable, under the common law test
that suggests considering the acts of a reasonably competent practitioner.105
Should these tests also hold for statements and even advertisements of CAM
products or services?
Most of the cases discussed above involve entities advertising health claims
in relation to supposedly therapeutic devices (eg, ion mats),106 persons making
spurious and completely baseless claims with no or very little evidence107
99	Hreckelton, above n 17, at 645.
100	Cancer Council Australia, Position Statement: Complementary and Alternative Therapies,
18 April 2013, at <http://wiki.cancer.org.au/preventk)n/Fosition_slalement_-_Coinple
incntary_and_alternative_therapies> (accessed 17 June 2013).
101	Refer to below; eg. Olivaylle Ply Ltd v Flottweg AC! (2009) 255 ALR 632; [20091 FCA 522;
BC200904211.
102	Medley Byrne and Co Ltd v Heller [ 1964] AC 465; 119631 2 All ER 575; 119631 3 WLR 101;
[19631 1 Lloyd's Rep 485.
103	Barker et at, The Law of Tons in Australia, 5th ed, Oxford University Press, Melbourne,
2012, p 486.
104	Civil Liability Act 2003 (Qld) s 22.
105	Dolam v Friern Hospital Management Committee [1957] 2 All ER 118; [1957] I WLR 582;
(1957) I BMLR 1 per Mc Nair J.
106	ACCC v Giraffe World Australia Ptv Ltd (1999) 95 FCR 302; 166 ALR 74; [19991 FCA
1161; BC9905234 at [2J.
107	Commissioner of Fair Trading, Department of Commerce v Perrett [2007] NSWSC 1130;
BC200708733.
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involving clients who were being treated for serious illnesses108 and
sometimes involving an abject failure to refer on to an orthodox medicine
practitioner at all or in a timely fashion.109
Is it appropriate to apply a requirement of scientific evidence to CAM,
which based on its procedures and traditions does not derive from an OM
scientific evidence base? Is it appropriate to apply OM scientific evidence to
CAM in regard to representations when in most cases there is no such
availability when well based traditional evidence may be available?
Traditional medicine concepts are being increasingly incorporated into
international standards. For example, the World Health Organization is
incorporating traditional medicine classifications into the latest version of the
International Classification of Diseases (ICD-U),110 which is the international
gold standard in reporting and defining disease; Standards Australia is
currently involved in formulating international (ISO) standards for traditional
Chinese medicine.111 As such it would follow that diese standards should also
be considered when evaluating CAM with a traditional evidence base.
It is often acknowledged that CAM has an appropriate niche when dealing
with self-limiting or chronic illness."2 In regard to the treatment of serious
illness, this needs to be dealt with carefully and aimed at dealing primarily
with symptoms rather than cures. This is acknowledged, for example, in cl 5
of the New South Wales Code of Conduct for Unregistered Practitioners. Most
CAM practitioners are dismayed by the activities of unprofessional CAM
practitioners as are the critics of CAM. CAM practitioners should be aware of
the limitations of their therapy. Any action in negligence against a CAM
practitioner will refer to peer opinion, which will often not rely upon scientific
evidence but may involve traditional evidence or anecdotal evidence or
'lower' forms of evidence in terms of the measures applied by orthodox
medicine.113 It is suggested that on that basis there is room to apply a more
flexible application of evidence to consumer issues involving CAM
practitioners.
When considering the level of scientific evidence for CAM, it should be
understood that OM is not compliant in the practice of evidence based
medicine (EBM). It has been suggested that half of conventional medical
treatment is of unknown effectiveness, with only 11% definitively beneficial
and 24% probably beneficial; additionally it is estimated that most of
Australian Medicare's 5000 items have not been comprehensively assessed for
safety, effectiveness or cost-effectiveness.114 Moreover, publication bias and
108	Commissioner of Fair Trading, Department of Commerce v Hunter [2008] NSWSC 277;
BC200802120.
109	Ibid.
110	At <hlIp://www,who-int/classilicalions/icd/revision/cn/> (acccsscd 17 June 2013).
111	Standards Australia — international (ISO) standards for traditional Chinese medicine; P F
Gao and K Watanabe, 'Introduction of ihe World Health Organization Project of the.
International Classification of Traditional Medicine' (2011) 9(11) Jul of Chinese Integrative
Medicine 1161.
112	M Weir. Alternative Medicine: A New Regulatory Model, Australian Scholarly Publishing,
Melbourne, 2005, p 107.
113	Shakvor v Situ 12000] 4 All ER 181; f2001J I WLR 410.
114	R Moynihan, 'Assaulting Alternative Medicine: Worthwhile or Witch Hunt?' (2012) BMJ-,
344:1075.
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the preponderance of unpublished trials have also recently brought into
question the usefulness of relying on clinical trial evidence alone.115
Additionally, the complexities of clinical practice may produce a divergent
evidence base, which does not lend itself easily to simplistic interpretation of
positive or negative evidence. Although often viewed as the gold standard of
evidence, meta-analyses of the same therapies may produce different results
depending on exclusion and inclusion criteria for studies, which may be
subjective. For example, using the same search strategies, homoeopathy's
effect can be found to be both belter than, no better than, or even worse than
placebo.1"1 When clinical trials arc used, the evidence for homoeopathy is
equivocal at best. However, observational and population health studies
consistently show demonstrable improvement in patients from homoeopathic
treatment.117 Additionally, observational or population-based studies may
demonstrate effect for treatments that are not supported by clinical trials.
Primary care itself provides a useful case study for this phenomenon, with
clinical trial data suggesting it is less cost-effective or clinically effective than
specialist care, whilst population-based data shows it to be the most effective
method through which to improve population health outcomes.118 Such
divergent results highlight legitimate differing interpretations of clinical
evidence, which need to be considered in weighing evidence.
The marketing of CAM goods and services could incorporate an approach
that applies the following parameters:
a.	Acknowledging where the evidence base is traditional in nature.
b.	Acknowledging where the evidence base is derived from
professional practice well accepted by a modality.
c.	Acknowledging where the evidence is based on scientific evidence.
d.	Acknowledging where the evidence base is a combination of the
above.
e.	A limitation on advertising of treatments for serious illnesses.
f.	An obligation to refer to orthodox medicine when the condition does
not resolve.
This process is recognised in regard to therapeutic goods under the
Guidelines for Levels and Kinds of Evidence to Support Indications and
Claims (guidelines).119 The guidelines provide the parameters for what may be
stated in advertising of pharmaceutical and CAM products directed towards
consumers. The guidelines do permit reference to traditional evidence. If it is
115	I Chalmers, P Glasziou and F Godlee, 'All Trials Must Be Registered and Results Published"
(2013) HMJ 346:fl05.
116	R Liidtkc and A L Rutlen, 'The Conclusions on the Effectiveness of Homeopathy Highly
Depend on (he Set of Analysed Trials,(2008) 61(12) Jnl of Clinical Epidemiology 1197.
117	C M Witt et at, 'Homeopathic Medical Practice; Long-term Results of a Cohort Study with
3981 Patients' (2005) 5(115) BMC Public Health, at <http://www.ncbi.nlni.nih.gov/pmc/
articles/PMC 1298309/> (accessed 17 June 2013); C M Witt el al, 'How Healthy Are
Chronically 111 Patients after Eight Years of Homeopathic Treatment? Results from a Long
term Observational Study' (2008) 8(413) BMC Public Health
<http://www.bi0medccntral.c0m/l47l-2458/8/4l3> (accessed 17 June 2013).
118	K Stangc and R Ferrer, 'The Paradox of Primary Care' (2009) 7(4) Annals of Family
Medicine 293.
119	Department of Health and Ageing, Therapeutic Goods Administration, Australian
Government, Guidelines for Levels and Kinds of Evidence to Support Indications and
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desired to make a claim in relation to registered or listed products, there are
different levels of evidence required under the guidelines.
To make an indication or claim based on evidence of traditional use,
sponsors must first assess the level of the evidence supporting the claim.
If you hold one of the following four sources of evidence, you hold general
level evidence:
1.	TGA-approved Pharmacopoeia.
2.	TGA-approved Monograph.
3.	Three independent written histories of use in the classical or
traditional medical literature.
4.	Availability through any country's government public dispensaries
for the indication claimed.
If you hold two of the above sources of evidence, you hold medium level
evidence.120 If you hold medium level evidence, you can make medium level
indications and claims, providing the evidence supports those
indications/claims. Medium level indications/claims include
indications/claims relating to:
•	Health enhancement;
•	Reduction of risk of a disease/disorder/condition;
•	Reduction in frequency of a discrete event;
•	Aids/assists in the management of a named
symptom/disease/disordcr/condition;
•	Relief of symptoms of a named disease, disorder or condition.121
Medium and general level indications and claims may only be made for minor,
self-limiting conditions. Serious diseases or disorders may not be mentioned
in medium or general level indications/claims.122
Consumer law in non-CAM professional contexts
In considering the way in which the legal concept of misleading or deceptive
conduct is determined and the role that scientific evidence plays in this
process, it is helpful to examine how this issue is dealt with in non-CAM
professional contexts. As noted above, the lack of scientific evidence for CAM
based therapies has in a number of cases resulted in a finding that a
representation is misleading or deceptive. As the option of ceasing all
representations in regard to clinical services and substances is not a practical
option, the necessity arises for CAM practitioners and manufacturers to clarify
how representations can be made that do not breach the ACL and/or
suggesting required changes to the law in this area.
The ACL is not prescriptive of the evidence required to prove misleading or
deceptive conduct. Typically, questions of proof in this area will be resolved
by the application of the general principles of the law of evidence and 'on the
Claims: For Noh-Regislerable Medicines, Including Complementary Medicines, and Other
Listable Medicines, Version I.I, April 2011, at <http://www.tga.gov.au/pdf/cin-evidence-
claims.pdf> (accesscd 17 June 2013).
120	Ibid, p 5.
121	Ibid, pp 6-7.
122	Ibid, p 7.
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balancc of probabililies'. WhcLhcr a particular representation will be held lo be
'misleading or deceptive' is always a complicated question, but more so where
the representation is open lo a complex or controversial interpretation. While
il is likely in this setting that expert evidence will be adduced as lo the truth
or falsity of the representation, the courts have made it clear thai the question
is ultimately one 'for the tribunal of fact and ... not . . . for any witness to
decide'.123 The treatment of expert evidence by the courts, particularly in the
context of the ACL, remains a vexed issue in Australia. This issue is
compounded in relation to CAM, where expert witnesses may not possess the
scientific or academic pedigrees of their counterparts in OM.
A leading case in this area is Tobacco Institute v AFCO.]24 Here the
Australian Federation of Consumer Organisations (AFCO) claimed that
advertisements containing representations suggesting there was little or no
scientific evidence that passive smoking was responsible for negative health
outcomes for non-smokers were misleading or deceptive under s 52 of the
Trade Practices Act.125 The plaintiff and defendant submitted scientific and
health professional evidence to the court.126 This case accordingly required
consideration of how best to deal with conflicting scientific and professional
evidence in the context of health issues. At first instance the judge proceeded
to compare and contrast the differing sets of evidence to determine which
evidence should be preferred.127 As he favoured the evidence submitted by the
plaintiff, judgment was given to the plaintiff.128 The defendant appealed to the
Full Court of the Federal Court. The court upheld the finding that the
representations were misleading or deceptive.129 The court held that where
there were two sides to a scientific debate it was not necessary for a judge to
decide which argument was to be preferred, rather whether the representation
was misleading.130 As the court determined that there was scientific evidence
of the negative impact of passive smoking and more than 'little' scientific
evidence of this, the representation was considered misleading or deceptive.131
Also of interest, albeit in the context of an engineering dispute, is Olivaylle
Pty Ltd v Flottweg AG.m In this case, Olivaylle entered into a contract with
Flottweg for the supply of an olive oil production line. Olivaylle asserted that
the production line was defective because il failed to comply with alleged
contractual specifications.133 They also alleged that Flottweg had been
123	Interlego AG v Croner Trading Fly Ltd (1992) 39 FCR 348 at 387; til ALR 577; 25 I PR
65; BC9203904.
124	Tobacco Institute of Australia Ltd v Australian Federation of Consumer Organisations Inc.
(1992) 38 FCR I; 111 ALR 61; 24 1FR 529; BC9203820.
125	Now s 18 of the ACL.
126	Tobacco Institute of Australia Lid v Australian Federation of Consumer Organisations Inc
(1992) 38 FCR 1; 111 ALR 61; 24 TPR 529; BC9203820.
127	Ibid.
128	Ibid.
129	Ibid.
130	Ibid.
131	Ibid.
132	Olivaylle Ply Ltd v Flottweg AG (No 4) (2009) 255 ALR 632; 120091 FCA 522;
BC200904211.
133	Ibid, at, [341.
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misleading or deceptive in representing the capacity of the production line.134
Flottweg denied that the production line was defective in the ways alleged and
alternatively argued that it had reasonable grounds for such representations.135
Logan J determined the representations asserted by Flottweg were made on
a reasonable basis because Flottweg had relied on company experience and
knowledge, the assessments of qualified and experienced consultants and
certified testing results of an independent authority.136 Flottweg had
considerable 'corporate knowledge and experience' arising from 40 years of
providing equipment.137 Logan J found that both witnesses for Flottweg had
'high tertiary engineering and trade qualifications and relevant experience'.138
Logan J took note of the fact that Flottweg's reliance on the assurances by
a Mr Nieuwkcrk, who had tertiary qualifications in engineering and
considerable experience in applied engineering in relation to nitrogen flushing
of industrial equipment, was not misplaced or uncritical, and Mr Nieuwkerk
had the qualifications and experience to make such assurances.139 Logan J
found that Flottweg had reasonable grounds to make the representations.140
From engineering to plumbing — another case to consider is Plastec
Australia Ply Ltd v Plumbing Solutions and Services Pty Ltd.ul Here, the
applicant Plastec carried on the business of designing, manufacturing and
selling plastic plumbing pipes and pipe-fittings, some of which are used in
plumbing and draining systems. Plastec alleged that the respondent Mr Martin
engaged in misleading or deceptive conduct by distributing communications
containing 17 representations that Plastec contended were not true.142 The
representations broadly suggested that Plastec's products did not perform as
required by relevant standards and in relation to their functionality.143
Mr Martin sought lo support his view by reference to his understanding of
the molecular bonding properties of the materials used, the chemical
properties of solvents and the nature and scope of the tests that he believed
should have been used to determine the long term fitness for purpose of the
fittings.144 Mr Martin called no other evidence in support of his case. Plastec
objected to the evidence of Mr Martin on the basis that he was not a polymer
chemist and, therefore, could not give expert opinion evidence concerning the
molecular bonding properties or particular joining methodologies and
properties of chemical solvent.145
Plastec called a substantial body of evidence to support its allegations.146
Greenwood J accepted the evidence of Plastec and found that Mr Martin had
134	Ibid, at [361
135	Ibid, at [371.
136	Ibid, at [2241.
137	Ibid, at [224(a)j.
138	Ibid, at [224(b)l.
139	Ibid, at [1031.
140	Ibid, at [222J.
141	Plastec Australia Pty Ltd v Plumbing Solutions and Services Pty Ltd [2012] FCA 5;
BC201200046.
142	Ibid, at [41.
143	Ibid.
144	Ibid, at [10].
145	Ibid, at [16].
146	Ibid, at [185].
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no basis on which to represent the asserlions lie had made regarding Plaslec
products.147
Greenwood J held that all of the statements made by Mr Martin were
misleading or deceptive as Mr Martin did not have a rational foundation to
represent them.148 Greenwood J was not satisfied that Mr Martin as a retired
plumber had the necessary expertise in a relevant discipline to form and give
evidence of an opinion regarding the functionality of Plastec fittings.149 He
further stated that even if Mr Martin's practical experience in the plumbing
industry and other roles were sufficient to provide him with a basis to form an
opinion surrounding the functionality of Plastec fittings, as his opinion failed
to address the body of data demonstrating compliance with Australian
Standards his evidence could not be preferred over the evidence of Plastec
demonstrating compliance.150
Rounding out this discussion is Tetra Pak Marketing Pty Ltd v Musashi Pty
Ltd,151 a case involving Tetra Pak, which manufactures and sells packaging
material for liquid food, and Musashi, which manufactures and sells sports
supplements. The parties came into conflict when Musashi created a brochure
for one of its products, 'P30', and within the document made a number of
representations regarding Tetra Pak products — namely, that Tetra Pak
packaging was made from aluminium, that aluminium can be toxic if ingested,
and that the aluminium in Tetra Pak packaging could migrate into food over
time and, if ingested, aluminium causes bodily injury.152
The key issue before the court was whether Musashi had reasonable
grounds for these assertions.153 Musashi provided as evidence all of the
material it had in its possession and had relied upon when making the
statements. The material consisted of:
1.	Seven pages of abstracts of 14 items that had appeared in scientific
journals, preceded by the words 'there are a number of papers
outlining health problems and aluminium';154
2.	Web pages consisting of profiles of individual scientists and a list of
publications by P F Zatta, who had research interests in
aluminium;155 and
3.	Web pages containing lecture note summaries for a lecture tilled
'Aluminium Toxicity in Plants'.156
Dr Trevor Mark Florence, an analytical chemist, gave evidence on behalf of
Tetra Pak. It was the opinion of Dr Florence that none of the evidence
supported the contention that substances contained in Tetra Pak packaging
147	Ibid, at [186J.
148	Ibid, at [368J.
149	Ibid, at. 13871.
150	Ibid, at [161.
151	Tetra Pak Marketing Pty Ltd v Musashi Fly Ltd [20011 FCA 1269; BC200105345.
152	Ibid, at [321.
153	Ibid, at 12.
154	Ibid, at [711.
155	Ibid, at [721.
156	Ibid, at [731-
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have aluminium concentrations that are high enough to cause toxicity or that
aluminium could leak into products contained in such packaging.157
Based on the evidence provided by Dr Florence, the material supplied by
Musashi and Musashi's failure to show that there was any other evidence upon
which it relied, apart from the documents, when making the representations,
Katz J held that Musashi did not have reasonable grounds to make the
assertions. Katz J focused solely on the absenee at the relevant lime of any
information that would have provided reasonable grounds for Musashi to
make the statements.158 The court held Musashi had not established a
reasonable basis; il was not necessary for the court to consider whether those
assertions were scientifically true or false.159
These cases involving misleading or deceptive conduct in connection with
health related (or tangentially health related) matters, but not focused on
health therapy, suggest that courts will accept (he opinions of
well-credentialed experts in their held as relevant expert evidence and that
scientific evidence is not necessarily required to determine whether a party has
a proper basis for a representation. Also noteworthy is the fact that industry
experience was a relevant consideration for determining the reasonableness of
a representation, especially in the absence of well-founded scientific evidence.
Is a different level required for CAM in consumer law
cases?
When dealing with claims of misleading representations in advertising or in
the course of practice by health practitioners, the case law suggests that these
claims are assessed based upon the need for high quality scientific evidence.
This is no doubt reflective of a view that when dealing with health matters
there is a need for good evidence to avoid personal injury. Il is increasingly an
aspect of the role of government to support societal expectations and, in
particular in relation to healthcare, to focus on regulation based upon the
assumed rationality of science.160 Government will tend to rely upon scientific
evidence as a means to justify budgetary decisions in regard to resource
allocation.161 But is the use of scientific evidence necessarily the best evidence
in all contexts (such as in CAM), and is it appropriate that the emphasis is
upon scientific evidence?
There is a good basis to argue that the use of scientific evidence is based
upon the hegemony enjoyed by OM in relation to health matters based upon
a specific type of healing that focuses on reductionist 'body as a machine'
concepts of healthcare.162 Foucault referred to it as the 'medical gaze'
whereby the medical doctor separates the body from person.163 Orthodox
medicine derives from the scientific model and encourages the type of
157	Ibid, at [781.
158	Ibid, at [84H85].
159	Ibid, at [861.
160	I fyioha, 'Law's Dilemma: Validating Complementary and Alternative Medicine and the
Clash of Hvidential Paradigms' (2011) 8 Evidence-based Complementary and Alternative
Medicine I at [34],
161	Ibid.
162	Weir, above n 112, p 70.
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scientific research preferred by OM. Orthodox medicine increasingly delines
knowledge on the basis of the results of clinical research rather than a reliance
upon observation or other empirical information that might be considered part
of the 'art' of the practice of medicine.164 Complementary and alternative
medicine relics upon very different principles and docs not necessarily comply
with this OM model.165 The OM perspective on evidence is based upon a
Western type of thinking that obscures health outcomes only evident from a
non-Western or traditional perspective.166
The type of scientific study sought by OM is a randomised controlled trial
(RCT):
RCT is a study design in which individuals are randomly allocated to at least two
groups, usually called the 'study' and the 'control' group. One group is subject to a
standardized experimental intervention, while the other group receives placebo or
standard treatment. The results arc assessed by rigorous comparison of the
outcome(s) in the study and control groups respectively. In order to limit bias, group
allocation maybe concealed to participants (ic blinding). RCTs are generally
considered as the most scientifically rigorous method of assessing the efficacy of an
intervention and, thus, represent the 'gold standard'.167
Some consider that the use of blinding and placcbo control is not integral to
RCT design and can be deleted, though this may open the study to criticism.168
The use of randomised double blind controlled trials may be considered the
'gold standard' of scientific evidence but there are limitations on the value of
this type of evidence that have been widely acknowledged in regard to its
application to CAM.169 This type of evidence does not necessarily fit well with
the type of healing philosophy applied by CAM and may suggest that the
focus on scientific evidence may not be supportable and applies an unduly
onerous and misplaced burden on CAM to justify efficacy and safety
claims.170 However, the limitations of randomised controlled trials arc not
solely related to CAM, with their limitations being increasingly acknowledged
in OM.171 Even when not relying on RCTs, there exist a number of
164	MR Tonclli and T C Callahan, 'Why Alternative Medicine Cannot Be Hvidenced-Based'
(2001) 76(12) Academic Medicine 1213 at 1214.
165	K F Schaffner, 'Assessments of Efficacy in Biomcdicine: The Turn toward Methodological
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167	M .1 Verhoef, "Assessing Efficacy of Complementary Medicine: Adding Qualitative Research
Methods to the "Gold Standard"' (2002) 8(3) .//;/ of Alternative and Complementary
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conventional rigorous research methodologies that may offer a more clinically
accurate evaluation tool for CAM, particularly in public health and health
services research.172
The focus on randomised controlled trials has led to a denigration of
non-experimental methods, suggesting that any other approach is invalid.173
Randomised controlled trials may not be useful where the number of subjects
is not large enough to measure infrequent adverse events or rare adverse
events; they do not deal well the health outcomes that may only arise far in the
future.174 In addition, if the effectiveness of a treatment depends upon a
subject's active participation, which is generally a significant issue in regard
to the self-help component of many CAM modalities such as naturopathy, or
is reliant on a subject's beliefs and preferences, the randomisation may impact
on the measured eflectivencss.175 Furthermore, much CAM relies upon a close
client-practitioner relationship, which an RCT will normally attempt to
exclude if possible. Randomised trials may be unnecessary when treatments
have dramatic effects where simple observation may suffice.176 Dramatic
effects of treatments are often reported by CAM practitioners and will often
form the basis of confidence for a practitioner in the efficacy of their modality
based upon their own anecdotal and empirical clinical practice.
The type of procedures and modalities applied by CAM may not be easily
applied to the type of approach used in relation to RCT. The use of blinding,
randomisation and placebos arc excluded by RCT, which avoids vital aspects
of the therapeutic process.177 Complementary and alternative medicine
interventions often apply multiple modalities, therapeutic substances and
procedures that do not deal well with reductionist approaches to health care
preferred by OM, where a single substance is identified and applied in a
controlled environment.178 The individually focused approach preferred by
CAM often applies different remedies to different persons, even if there is a
similar or same illness identified based upon normal OM approaches.179
Complementary and alternative medicine regularly involves treatment of
complex, often chronic conditions and may not aim to restore balance or
harmony rather than to treat any particular condition.180
One approach to deal with these types of methodology issues for CAM has
been to consider pragmatic trials so that a whole system of healing is assessed
in their context to allow highly individualised treatments involving some
acknowledgement of patient views. Qualitative evidence may be used in
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174	Black, above n 169, at 215.
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addition to RCTs to deal with issues such as the clicnt-praclilioner
relationship.181 'Qualitative research consists of the investigation of
phenomena in their natural context, in an in-depth holistic fashion through the
collection of rich narrative data'.182 The aim of this type of research is not to
provide quantified answers but to understand social phenomenon in natural
settings including an understanding of practitioner/client roles and influences.
If an RCT shows no treatment efficacy, it docs not indicate if the intervention
worked in other ways that may he unexpected. This issue is problematic, as
much quantitative research may not properly deal with the context and may
focus primarily on the physical to the exclusion of meaning, purpose and
spirituality and will simply apply the average result.1"3
The call for RCT to provide the basis of an evidence based CAM is, in
reality, a call for CAM to accept the epistemic framework of CM, which is a
demand based on a philosophical view:
By demanding thai alternative medicine become evidence-based, EBM seeks to
define itself not only as orthodoxy in Western Medicine, but also as the primary
arbiter of all medical knowledge.184 The alternative claim that dircct observation of
the individual patient remains preferable to reliance on the results of clinical trials,
then, cannot simply be dismissed.185
Traditionally, a medical intervention is deemed successful when an
intervention is effective for one individual. In the modern context, public
health considerations tend to focus upon demonstrated effectiveness across a
population. Randomised controlled trials do not provide the ability to
determine the effectiveness of any particular intervention.186 Randomised
controlled trials do not deal well with non-measureablc impacts of
intervention involving a particular individual. Many CAM practices rely upon
important but essentially immeasurable measures such as 'Qi' that is
recognised in TCM as an invisible force which gives life to ail living things.
In this sense, RCTs have difficulty in falsifying the claims of benefits by
individuals. Tonelli comments:
To prefer indirect evidence, such as that obtained from clinical trials, over primary
experience represents an epistemic choice not scientific necessity. CAM and CAM
practitioners, therefore, can continue to emphasize individual outcomes without
inconsistency even when the therapies they utilize have failed to demonstrate
efficacy in controlled clinical trials.187
lyioha argues for:
|A| regulatory system that is accommodative of different evidential paradigms. It
suggests that the acceptable evidence must be that which takes into account the
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unique nature of CAM and advocates for a modified methodological framework,
which acknowledges the belief systems and values inherent in CAM as part of the
therapeutic process itself.188
lyioha suggests thai anthropological or ethnographic research processes may
be of value in applying that type of research to determine the evidence basis
for CAM to deal with factors that may not be visible from scientific methods
by looking primarily al the interaction between a particular patient and a
health practitioner.189 The techniques of investigation for this type of research
are through personal and intuitive patterns of knowledge. lyioha concludes
that RCTs are not designed to provide optimal research outcomes for therapies
like CAM.190 lyioha suggests that 'science is structured to remove any human
factors from the context of the study, setting up a model that is detached from
feelings, meaning and subjective experiences'.191 Since research
methodologies 'are not considered to be independent from their paradigm of
reference', it can be said, therefore, that 'the methods used ... for
conventional medical research reflect the paradigm on which they were
founded'.192
Other scholars have noted that the adoption of a single evidential paradigm
for CAM is less than optimal. Lewith et al assert that 'no single research
methodology in itself yields all the knowledge necessary with respect to
effectiveness, efficacy, safety, and patient/doctor treatment preferences'.193
Vickers affirms that the RCT indeed 'does not aim to' provide the answer to
'all questions of interest in health care'.194 These views have prompted some
scholars to demand multiple research methodologies. Is it possible to develop
a pluralistic approach to research methods that retains the value of Western
science for medicine and yet respects the diversity of radically different
concepts about life, health and service.195
In addition, when scientific evidence of efficacy is provided, such as in the
case of homoeopathy, it is met by a view based upon the perspective of 'prior
plausibility'. Prior plausibility suggests that the lack of a plausible biological
mechanism automatically invalidates the research result.196 This view draws
upon the approach that existing scicntific knowledge is an adequate basis to
review the quality of all health interventions, and the result from a therapy that
is implausible is that it should be rejected, otherwise the basis of OM science
would be overturned.197 The view of such research is that any therapeutic
result is impossible, so it must be based upon another source, ie placebo.
However, 'citing biological plausibility as an explanation for accepting a lack
of evidence in conventional medicine over complementary medicine is
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flawed'.198 'Biological plausibility depends on contemporary biological
knowledge and we should not dismiss an association because it may be new
to science or medicine.'199 Nor should traditional evidence or theories be
dismissed solely because they do not fit easily within scientific concepts. For
example, linguistic examination of traditional Chinese medicine concepts has
suggested that traditional terminology may in fact be describing similar
phenomena to scientific language, but simply expressed in a different way.200
Reliance on current scientific evidence to judge therapies may be limiting. In
1977, the Webb report investigating regulation of naturopathy, in addition to
chiropractic and osteopathy, dismissed the effectiveness of herbal medicines,
suggesting that as 'the thoroughness with which the pharmaceutical industry
has surveyed the global flora for pharmacologically active substances renders
the probability of any significant range of effective herbal medicine most
unlikely'.201 Had this approach been taken at face value, several therapeutic
agents, including the world's current gold-standard anti-malarial treatment,202
would have been dismissed.
Suggested model
It is not intended that this article should provide a counsel to not require an
adequate evidence base for representations made about CAM. There are
justified concerns expressed by many about the outrageous representations
made by some unregistered health practitioners, and it is appropriate that these
practices are dealt with. But regulatory theory would suggest the need to
ensure proportionality and parsimony in that the measures employed are only
as intrusive as is necessary to meet the regulatory objectives.203 This may
reduce the cost of enforcement as discussed above, which may not be
necessary if the level of enforcement is pitched at lower levels of enforcement
and results in a positive outcome for the regulatory authority. What this article
does argue for is an acknowledgement that the type of evidence preferred by
OM is either not obtainable for CAM for cost reasons or, if obtained, is
inherently unable to deal with the nature of the modalities under
consideration. This suggests a need to consider how health outcomes that need
to be at the heart of any regulatory system for CAM should acknowledge the
role and value of CAM. The case law has specified the cases where
representations in advertising and claims made by some practitioners have
been found to have breached consumer laws. In many cases, there is no
evidence to support those claims. In a few cases, the quality of evidence to
support claims has been deemed insufficient to provide the required level of
evidence. Cases dealing with non-health therapy issues indicate that there is
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no necessity to provide scientific evidence for a representation, rather a court
needs to conclude on the balance of probabilities whether there is a reasonable
basis for that representation based upon expert evidence. In negligence cases
against CAM practitioners, the evidence of expert CAM practitioners is
accepted as influential evidence even in the face of other contrary OM expert
evidence.204 This issue arises under the claims guidelines,2011 which allow the
use of traditional evidence to justify certain types of representations. A similar
level of evidence should be accepted in the case of CAM advertising and
representations generally and in effect apply some of the processes applied by
the Australian Register of Therapeutic Goods process more widely.
In the case of advertising or representations in regard to curing or treating
serious illnesses, there is a basis to argue for some limitations on
representations in that circumstance requiring high quality scientific evidence.
Conclusion
Komesaroff et al have suggested that, rather than suppressing all approaches
to health care that we cannot understand or condone:
[A] system of safeguards should be established to minimise risk, while continuing
to protect the rights of consumers to choose their own health-care practices. Such
safeguards should include legal, professional and conceptual criteria and target
specific rogue practices while protecting and regulating others.2"6
Medicine is a complex craft and much of its success depends on its ability to draw
on a wide array of practices ... We cannot afford to be overconfident about our own
approaches or dismissive of those of others.207
The analysis above demonstrates a substantial demand for CAM in Australia.
The national regulatory system for consumer protection that currently
provides adequate processes to limit misleading or deceptive conduct by
practitioners and manufacturers though the level of evidence required to
satisfy legal tests may require reconsideration. Based upon a risk assessment
for traditional evidence and different forms of scientific or professional
evidence, it is possible to protect consumers and still provide them with viable
health services and products (hat they or their practitioner determines is
efDcacious and safe. Within this regulatory system, il will always be necessary
to have available remedies to control the activities of rogue practitioners who
act contrary to professional standards as cxamplcd in some of the cases
discussed above and to apply standard professional parameters. The task is to
design a regulatory system that does not allow the exploitation of vulnerable
clients while allowing those who, in applying their autonomy, are entitled to
explore other healthy regimes and allows manufacturers and practitioners to
provide the substances and modalities that are in demand without undue
regulation based upon a philosophy foreign to those choices.
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